Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer

Seventeen patients with refractory KRAS mutated and wild type metastatic colorectal adenocarcinoma received single agent ganetespib in a single institution phase II study. The drug was well tolerated but did not yield any responses, although two patients achieved durable stable disease. BACKGROUND:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Colorectal Cancer
Main Authors: Cercek, Andrea, Shia, Jinru, Gollub, Marc, Chou, Joanne F., Capanu, Marinela, Raasch, Pamela, Reidy-Lagunes, Diane, Proia, David A., Vakiani, Efsevia, Solit, David B., Saltz, Leonard B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5489410/
https://ncbi.nlm.nih.gov/pubmed/25444464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clcc.2014.09.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados